Jacqueline Elizabeth Shea Net Worth

The estimated Net Worth of Jacqueline Elizabeth Shea is at least $2.24 millió dollars as of 15 May 2024. Jacqueline Shea owns over 17,745 units of Inovio Pharmaceuticals Inc stock worth over $270,941 and over the last 6 years he sold INO stock worth over $812,192. In addition, he makes $1,157,030 as Chief Operating Officer at Inovio Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Jacqueline Shea INO stock SEC Form 4 insiders trading

Jacqueline has made over 15 trades of the Inovio Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 17,745 units of INO stock worth $116,230 on 15 May 2024.

The largest trade he's ever made was exercising 92,778 units of Inovio Pharmaceuticals Inc stock on 26 February 2023 worth over $607,696. On average, Jacqueline trades about 29,300 units every 76 days since 2019. As of 15 May 2024 he still owns at least 41,365 units of Inovio Pharmaceuticals Inc stock.

You can see the complete history of Jacqueline Shea stock trades at the bottom of the page.

Jacqueline Elizabeth Shea biography

Dr. Jacqueline Elizabeth Elizabeth Shea Ph.D. serves as Chief Operating Officer of the Company. Dr. Shea has served as our Chief Operating Officer since March 2019. Prior to joining us, Dr. Shea served as chief executive officer of Aeras, a nonprofit organization developing tuberculosis vaccines, from August 2015 to December 2018, and as its chief operating officer from April 2014 to August 2015. Dr. Shea previously served as Vice President of Business Development, Europe for Emergent BioSolutions Inc. from May 2013 to March 2014, having previously served as Senior Director of Business Development for Emergent BioSolutions from 2005 to 2008. She was general manager of The Oxford-Emergent Tuberculosis Consortium, a global health joint venture formed between Oxford University and Emergent BioSolutions, from 2008 to 2013. She started her career as a post-doctoral researcher at Imperial College, London. Dr. Shea holds a Ph.D. from the National Institute for Medical Research and a B.S. in applied biology from University of Bath.

What is the salary of Jacqueline Shea?

As the Chief Operating Officer of Inovio Pharmaceuticals Inc, the total compensation of Jacqueline Shea at Inovio Pharmaceuticals Inc is $1,157,030. There are 2 executives at Inovio Pharmaceuticals Inc getting paid more, with Jong Kim having the highest compensation of $2,588,530.

How old is Jacqueline Shea?

Jacqueline Shea is 55, he's been the Chief Operating Officer of Inovio Pharmaceuticals Inc since 2019. There are 8 older and 6 younger executives at Inovio Pharmaceuticals Inc. The oldest executive at Inovio Pharmaceuticals Inc is Simon Benito, 75, who is the Independent Chairman of the Board.

What's Jacqueline Shea's mailing address?

Jacqueline's mailing address filed with the SEC is 660 W. GERMANTOWN PIKE, , PLYMOUTH MEETING, PA, 19462.

Insiders trading at Inovio Pharmaceuticals Inc

Over the last 20 years, insiders at Inovio Pharmaceuticals Inc have traded over $23,656,819 worth of Inovio Pharmaceuticals Inc stock and bought 1,958,377 units worth $5,174,071 . The most active insiders traders include Austin W & Greenhouse David..., Jong Joseph Kim és Felix Theeuwes. On average, Inovio Pharmaceuticals Inc executives and independent directors trade stock every 22 days with the average trade being worth of $745,390. The most recent stock trade was executed by Michael John Sumner on 30 June 2024, trading 2,917 units of INO stock currently worth $19,106.

What does Inovio Pharmaceuticals Inc do?

inovio is revolutionizing the fight against cancer and infectious diseases. our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. with an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. partners and collaborators include roche, medimmune, university of pennsylvania, darpa, drexel university, nih, hiv vaccines trial network, national cancer institute, u.s. military hiv research program, and university of manitoba. for more information, visit www.inovio.com.

Complete history of Jacqueline Shea stock trades at Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc executives and stock owners

Inovio Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Jong Kim,
  President, Chief Executive Officer, Director
• Dr. J. Joseph Kim,
  CEO, Pres & Director
• Jacqueline Elizabeth Shea,
  Chief Operating Officer
• Peter Kies,
  Chief Financial Officer
• Laurent Humeau,
  Chief Scientific Officer
• Peter D. Kies,
  Chief Financial Officer
• Dr. Laurent M. Humeau,
  Chief Scientific Officer
• Dr. Jacqueline E. Shea Ph.D.,
  Chief Operating Officer
• David Weiner,
  Director
• Lota Zoth,
  Independent Director
• Simon Benito,
  Independent Chairman of the Board
• Ann Miller,
  Independent Director
• Wendy Yarno,
  Independent Director
• Jay Shepard,
  Independent Director
• Asli Gevgilili,
  Chief HR Officer
• Robert L. Crotty J.D.,
  Gen. Counsel
• Robert J. Juba Jr.,
  Sr. VP of Biological Manufacturing & Clinical Supply Management
• Dr. Jeffrey Skolnik,
  Sr. VP of Clinical Devel.
• Dr. Ami Shah Brown,
  Sr. VP of Regulatory Affairs
• Jessica C. Lee MS, MPH,
  Sr. VP of Clinical Operations & Global Integration
• E. J. Brandreth,
  Sr. VP of Quality Assurance
• Ben Matone,
  Director of Investor Relations
• Morton Collins,
  Director
• George Bickerstaff,
  Director
• Adel Mahmoud,
  Director
• Mark Bagarazzi,
  Chief Medical Officer
• Niranjan Sardesai,
  Sr. VP Research & Development
• Nancy Wysenski,
  Director
• Avtar S Dhillon,
  President & CEO
• Angel Cabrera,
  Director
• Austin W & Greenhouse David...,
  10% owner
• Dietmar P Rabussay,
  V.P. Research & Development
• George F. Iii Mc Hugh,
  Vice President, Operations
• Eugene A Larson,
  Director
• Felix Theeuwes,
  Director
• Robert S Goodenew,
  V.P. Corporate Development
• Michael Fons,
  VP, Corporate Development
• Kevin Rassas,
  Sr. VP Business Development
• Cheryl Jo White,
  Chief Medical Officer
• Tee Khiang Ng,
  Director
• Robert William Rieder,
  Director
• James L Heppell,
  Director
• David J Williams,
  Director
• Punit Dhillon,
  VP, Finance & Operations
• Riaz Amirali Bandali,
  Director
• Stephen Rietiker,
  Director
• Beng Lee Gan,
  Director
• Tazdin Esmail,
  Director
• Keith H Wells,
  Director
• Chin Cheong Chong,
  Director
• Roger D Dansey,
  Director
• Michael John Sumner,
  Chief Medical Officer